NEW YORK (GenomeWeb News) – Lexicon Pharmaceuticals said today it will use Nuevolution’s technology to identify small molecule lead compounds against a range of highly validated drug targets.
 
Under the agreement, Lexicon will pay Nuevolution an upfront payment and would also pay milestone payments and royalties on compounds that are identified using the Nuevolution Chemetics technology if candidate molecules advance through preclinical and clinical development and onto the market.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.